OrbiMed’s Immunovant IMVT Stock Holding History

OrbiMed’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-78,500	Closed	-$1.94M	–	116
2024 Q4	$1.94M	Buy	+78,500	New	+$2.23M	0.04%	103
2020 Q3	–	Sell	-354,575	Closed	-$8.63M	–	152
2020 Q2	$8.63M	Buy	354,575 +175,075	+98%	+$3.75M	0.12%	105
2020 Q1	$2.79M	Buy	+179,500	New	+$2.7M	0.05%	120

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

OrbiMed's IMVT Position: Q1 2025 in Review

OrbiMed sold out of Immunovant (IMVT) in Q1 2025, closing a stake of 78,500 shares — an estimated $1.94M sold.

OrbiMed first reported a position in IMVT in Q1 2020 and held it in 3 quarters. The position peaked at $8.63M in Q2 2020. 193 funds tracked by Wall St. Rank hold IMVT as of Q1 2025.

OrbiMed reported no remaining Immunovant position as of Q1 2025 after selling out during the quarter.
OrbiMed sold 78,500 Immunovant shares in Q1 2025, an estimated $1.94M.
OrbiMed first reported a position in Immunovant in Q1 2020 and held it in 3 quarters.
OrbiMed's Immunovant position peaked at $8.63M in Q2 2020.
193 funds tracked by Wall St. Rank held Immunovant as of Q1 2025.

Based on OrbiMed's 13F filing for Q1 2025, filed 15 May 2025.